haematology
Blood cancers

After CAR T-cell therapy, quality of life is good for people with RR DLBCL

The value of CAR T-cell therapy in refractory or relapsed diffuse large B cell lymphoma (RR DLBCL) has been further boosted by a study showing the salvage therapy also leads to better physical and social function in addition to its impressive survival outcomes in patients with advanced disease. In a post hoc analysis of patient-reported ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic